Target Price | $27.33 |
Price | $18.69 |
Potential |
46.25%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Cidara Therapeutics, Inc. 2025 .
The average Cidara Therapeutics, Inc. target price is $27.33.
This is
46.25%
register free of charge
$33.00
76.57%
register free of charge
$24.00
28.41%
register free of charge
|
|
A rating was issued by 4 analysts: 4 Analysts recommend Cidara Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Cidara Therapeutics, Inc. stock has an average upside potential 2025 of
46.25%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 63.91 | 9.40 |
0.59% | 85.29% | |
Net Margin | -57.91% | -1,848.19% |
1,128.19% | 3,091.30% |
2 Analysts have issued a sales forecast Cidara Therapeutics, Inc. 2024 . The average Cidara Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Cidara Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Cidara Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
2023 | -57.91% | 1,128.19% |
---|---|---|
2024 |
-1,848.19%
3,091.30%
Unlock
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -5.25 | -24.64 |
1,120.93% | 369.33% | |
P/E | negative | |
EV/Sales | 0.88 |
4 Analysts have issued a Cidara Therapeutics, Inc. forecast for earnings per share. The average Cidara Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Cidara Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current | 0.31 | 11.43% |
---|---|---|
2024 |
0.88
183.13%
Unlock
|
Current | 5.00 | 340.09% |
---|---|---|
2024 |
14.01
180.32%
Unlock
|
Cidara Therapeutics, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.